Edgewise Therapeutics (EWTX) Q3 2026 earnings review
Edgewise collects $1.4 billion in cash and advances heart trials
Edgewise Therapeutics, a developer of heart muscle medicines, closed the sale of its muscular dystrophy business while advancing two cardiac trials. The deal brought in $1.4 billion of upfront cash at closing, lifting the bank balance to $1.74 billion. Interest on that cash and lower research bills narrowed the quarterly loss, excluding the sale, to $27 million by our math. Chief executive Kevin Koch dosed the first patient in a mid-stage heart failure study and kept the late-stage heart trial on schedule for this year.
| Cash and marketable securities | $1.74B $460.7M last quarter |
|---|---|
| Net loss, excluding the asset sale | $26.6M $40.7M loss a year ago (by our math) |
| Research and development costs | $31.6M -16% from a year ago |
| EDG-7500 Phase 3 trial start plan | Unchanged on track for year-end 2026 |
⚖️ Verdict: 🟢 Bullish
The story got better because the completed sale funds both heart drugs while interest income now pays over a third of operating bills. One caution: holdbacks and taxes cut into the proceeds, as closing cash came in $154 million below the $1.55 billion headline price and a $155 million tax charge pushed liabilities up.
The question now is how fast spending climbs back up once the late-stage heart study begins. Either interest income keeps covering a large share of costs, or two big heart trials and rising overhead burn through the cash cushion faster. The fourth-quarter research bill and Phase 3 trial design will tell.
🐂 Bull Case
Asset Sale Cash Covers Over A Third Of Costs
Edgewise Therapeutics, a developer of pills for heart muscle diseases, closed the sale of its muscular dystrophy drug sevasemten to French pharmaceutical group Servier in July. The deal handed the US biotechnology company $1.396 billion in upfront cash at closing. That payment lifted total cash and marketable securities to $1.74 billion at the end of September, up from $460.7 million three months earlier.
Because the cash pile is now almost four times larger, interest income jumped 166% from a year ago to $16.5 million. At the same time, shedding the muscular dystrophy trials lowered research and development costs by 15.8% to $31.6 million. By our math, interest on the bank balance paid for 35.8% of total operating expenses this quarter, up from 13.2% a year ago.
What to watch: quarterly interest income against research spending in the fourth quarter. Once the costly late-stage heart trial begins, operating expenses will climb back up and reduce the share of bills paid by interest.
Heart Failure Drug Enters Mid-Stage Patient Testing
With its muscle disease unit sold, Edgewise relies entirely on two experimental heart medicines. The second of those drugs is EDG-15400, what chief executive Kevin Koch calls "our selective cardiac sarcomere modulator designed to address impaired cardiac relaxation in HFpEF" — a common form of heart failure where stiff heart muscle cannot relax properly between beats.
During the third quarter, the drugmaker dosed its first patient in the mid-stage Phase 2 trial, named EQUINOX-HFpEF. Hitting this milestone met the company's plan to start patient testing in the second half of 2026, moving the pill out of healthy volunteers and into adults with active heart failure.
What to watch: the target date for initial patient results from the EQUINOX-HFpEF study. Early human data will show whether the pill relaxes stiff heart tissue in sick patients as it did in animal tests.
Lead Heart Pill Stays On Schedule For Late-Stage Trial
Edgewise's lead medicine is EDG-7500, an oral drug for hypertrophic cardiomyopathy (HCM), an inherited condition where thickened heart muscle makes it hard for the heart to pump blood. In August, the biotech group presented positive 12-week results from Part D of its mid-stage CIRRUS-HCM study at a medical congress in Europe and published its lab findings in a peer-reviewed journal.
Those data sets showed the drug helped the heart muscle relax without weakening its pumping strength, a side effect that limits rival medicines. Koch said "we expect to initiate our Phase 3 trial by year-end 2026", keeping the company's most important clinical deadline intact.
What to watch: confirmation before December 31 that the first patient has entered the Phase 3 HCM study. Starting on time keeps the company's lead drug on schedule and unlocks the next stage of testing.
🐻 Bear Case
Holdbacks And Taxes Cut Into The Asset Sale Windfall
When Edgewise announced the Servier deal last quarter, it highlighted a $1.55 billion upfront price and a combined $2.01 billion cash balance before taxes and fees. The third-quarter accounts show a smaller net addition to the bank account once closing holdbacks and tax bills took effect.
- Upfront cash received at closing: $1.396 billion, or $154 million below the $1.55 billion headline price by our math
- Ending cash and securities: $1.744 billion, or $266.8 million below last quarter's pre-tax figure by our math
- Third-quarter tax expense: $155.3 million booked on the sale
- Total liabilities: $147.4 million, up $115.7 million from June by our math
The company noted that the $1.348 billion accounting gain reflects "amounts associated with the general indemnification arrangement" and transition services, while its risk factors warn it may not receive "amounts held in escrow". Meanwhile, the $115.7 million jump in liabilities indicates that most of the $155.3 million tax bill had not yet left the bank on September 30.
What to watch: the exact escrow balance and cash taxes paid in the full third-quarter filing. Paying off the remaining tax liability will pull the cash balance down further in coming quarters.
Overhead Kept Rising After Selling The Lead Program
Handing the muscular dystrophy business to Servier removed Edgewise's biggest research bill, so research and development spending dropped 33.6% from last quarter to $31.6 million. In contrast, general and administrative costs — executive pay, stock awards, legal fees and office overhead — moved the other way, rising 55.3% from a year ago and 1.2% from last quarter to $14.6 million.
The company said it "expanded its organizational capabilities to support clinical development" and paid higher professional fees. Because research spending fell while overhead grew, administrative costs consumed 31.6% of total operating expenses this quarter, up from 20.0% a year ago by our math.
What to watch: fourth-quarter administrative expenses once deal legal fees fade. If overhead stays near $15 million a quarter with one fewer business unit, permanent staff costs have stepped up.
One-Time Profit Unmasked Eleven Percent Share Dilution
As long as Edgewise reported quarterly net losses, accounting rules excluded employee stock options and awards from its per-share math because counting them would make the loss per share look smaller. Booking a $1.17 billion net profit from the Servier sale forced all of those extra shares into the diluted share count for the first time.
Basic shares rose 3.2% from a year ago to 108.9 million, but diluted shares reached 120.9 million — 11.0% higher than the basic count by our math. That 12.0 million share gap lowered diluted earnings per share to $9.65 against $10.71 on a basic count, showing how much of the company's upside belongs to option holders.
What to watch: any share buyback plan or special dividend announcement in the annual report. With $1.74 billion in cash and no debt, management has not yet said whether it will offset employee dilution.
💲 Other KPIs
Total operating costs fell 25.5% from last quarter and 1.5% from a year ago, ending three straight quarters of rising spend. Selling the sevasemten program in July cut quarterly research bills by $16.0 million from the second quarter, while administrative expenses edged up by $0.2 million.
Reported net income was $1.17 billion, or $9.65 per diluted share, because of the sevasemten sale. Stripping out the $1.35 billion gain and $155.3 million tax charge leaves a net loss of $26.6 million, or $0.24 per basic share by our math, narrower than the $40.7 million loss a year ago.
🔮 Guidance
Unchanged. Edgewise still plans to start its pivotal Phase 3 study of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy before the end of 2026. With two months left in the year and Phase 2 Part D results already presented in August, the timeline looks achievable.
❓ Key Questions
Why did upfront cash fall $154 million below $1.55 billion?
Edgewise announced a $1.55 billion upfront price in July but collected $1.396 billion at closing. Investors need to know how much sits in escrow, what indemnification rules govern it, and when the company can collect the difference.
How much of the $147 million in liabilities is unpaid tax?
Total liabilities jumped by $115.7 million this quarter alongside a $155.3 million tax expense. When the company pays that tax bill in cash, its $1.74 billion bank balance and future interest income will drop.
What is the patient enrollment target for the EDG-7500 trial?
The Phase 3 HCM study is set to start by December, but management has not disclosed its trial size, duration, or total cost. Those figures determine how fast research spending will climb in 2027.
Will Edgewise return any Servier cash or keep all $1.74 billion?
Selling sevasemten left the company with far more cash than two heart trials require right now, while employee options added 12 million shares to the diluted count. Management has not stated its capital return policy.